January to June 2026:
HARTMANN once again increases revenue and earnings

Heidenheim, 18 August 2026. In the second quarter of 2026, HARTMANN was able to further build on its good development in the first three months of the year, closing the first half of 2026 on a very positive note.

Organic sales growth amounted to 3.3% compared to the same period last year. Sales revenues increased to EUR 1,252.0 million. Adjusted EBITDA came in at EUR 151.7 million, up EUR 25.9 million from the prior-year figure. The adjusted EBITDA margin increased from 10.4% to 12.1%.

Business performance in the first half of 2026 continued to benefit from the effects of the successfully completed Transformation Program. Building on this, HARTMANN continues to pursue its PLUS₂₀₃₀ strategy, which focuses on profitable growth, innovation and productivity, while placing additional emphasis on sales efficiency and strengthening customer proximity.

In the Wound Care segment, the growth achieved was primarily attributable to advanced wound care with atraumatic dressings as well as positive business performance in the U.S. However, changes in reimbursement policies had a dampening effect. In France, these changes already took effect in 2025 and there is uncertainty about the further development on this matter in Germany.

In the Incontinence Management segment, key growth drivers were incontinence pants and products for managing moderate to severe incontinence.

The Infection Management segment also recorded growth, primarily attributable to products for hand and surface disinfection, surgical sets as well as surgical and examination gloves.

The Complementary Group Divisions segment reported sales revenues slightly below the prior-year period. This was primarily due to the performance of Kneipp, while the businesses of the CMC and KOB Groups remained stable.

HARTMANN expects that the increased costs for materials, energy and freight resulting from the war in Iran will have a more significant impact on the second half of 2026. These cost increases can only be partially offset by pricing measures.

For the full fiscal year 2026, HARTMANN confirms its forecast and continues to expect moderate organic sales growth and adjusted EBITDA in the range of EUR 270 to 310 million.

In 2027, new regulations in statutory health insurance and changes currently planned as part of the long-term care reform will have a negative impact on HARTMANN’s previously positive revenue and earnings performance.

Further information on financial topics at HARTMANN can be found (in German) at: https://corporate.hartmann.info/en/investor-relations

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.